A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics

Exclusion Criteria

• •1. Diagnosed with guttate psoriasis, pustular psoriasis, erythrodermic psoriasis, or drug-induced psoriasis (e.g., psoriasis caused by beta blockers, calcium channel inhibitors, etc.) at screening;
• •2. Previously treated with IBI112 or other IL-23 inhibitors;
• •3. Treated with two biologics for psoriasis within 4 months prior to screening;
• •4. Treated with topical therapy for psoriasis within 2 weeks prior to the first dose administration, or treated with systemic non-biological agents or phototherapy within 4 weeks prior to the first dose administration;
• •5. Treated with Natalizumab, or B/T cell regulators (e.g., Rituximab, Abatacept, or Visilizumab) within 12 months prior to the first dose administration;
• •6. Not willing to avoid constant sunshine and other ultraviolet light sources exposure during the study;
• •7. Treated with an investigational biologic within 6 months prior to the first dose administration, or any investigational therapy within 30 days, or an investigational drug within 5 half-lives, or currently participating in a clinical study.